Latest Conference Coverage

Incorporating Digital Cognitive Assessments in Real-World Practice: Nicole Fowler, PhD

The director of research for internal medicine and geriatrics at Indiana University School of Medicine discussed the advantages digital assessments bring to clinics, and what role they will play in the coming years. [WATCH TIME: 3 minutes]

Uncovering Ethnic, Racial Differences in Multiple Sclerosis Onset: Farren B. S. Briggs, PhD, ScM

The associate professor in the department of population and quantitative health sciences at Case Western Reserve University School of Medicine talked about the presentation of multiple sclerosis in Latinx individuals compared with White Americans. [WATCH TIME: 5 minutes]

Enhancing Consistency in Neuroimaging With AI and Image Harmonization: Lianrui Zuo, MSE

The PhD student in the department of electrical and computer engineering at Johns Hopkins University discussed the use of artificial intelligence and image harmonization techniques to address the challenges caused by multisite effects in neuroimaging. [WATCH TIME: 4 minutes]

Ensuring Safe Pregnancy and Postpartum Care for Patients With Multiple Sclerosis: Anna Shah, MD

The assistant professor of neurology at the University of Colorado School of Medicine talked about the importance of addressing family planning with patients with multiple sclerosis. [WATCH TIME: 5 minutes]

Retrospectively Exploring De-Escalation of Multiple Sclerosis Medication: Carolyn H. Goldschmidt, DO

The neurologist at NorthShore University Health System in Chicago discussed a retrospective study on patients with multiple sclerosis who switched from high or moderate efficacy disease-modifying therapies to lower efficacy ones. [WATCH TIME: 5 minutes]

Comparing Ublituximab and Teriflunomide in Improving Fatigue in MS: Enrique Alvarez, MD, PhD

The associate professor of neurology at the University of Colorado School of Medicine discussed results of phase 3 studies assessing therapeutics on the impact of fatigue experienced by patients with multiple sclerosis. [WATCH TIME: 5 minutes]

Epigenetic Therapy Demonstrates Efficacy in APOE Reduction for Alzheimer Disease

Research shows that carrying the APOE e4 variant significantly increases lifetime risk for late-onset Alzheimer disease, and additional evidence suggests that lowering the variant expression may be a promising therapeutic target for the disease.

Early Intervention and Disease Prevention With a Novel Epigenome Approach: Boris Kantor, PhD

The associate research professor of neurobiology at Duke University discussed an innovative epigenome editing approach that shows promising prospects for patient improvement, disease prevention, and potential use in Alzheimer disease prophylactic work. [WATCH TIME: 3 minutes]

Targeting Neuroinflammation as a Novel Approach in Brain Health for Alzheimer Disease: RJ Tesi, MD

The chief executive officer at INmune Bio discussed a unique approach from a phase 1 study targeting neuroinflammation in the brain to improve cognitive abilities and maintain memory. [WATCH TIME: 5 minutes]

Integrating Blood-Based Biomarkers as a Revised Approach to Diagnosing Alzheimer Disease

Maria Carrillo, PhD, chief science officer for the Alzheimer's Association, talked about the release of the updated diagnostic guidelines for Alzheimer disease, which incorporate plasma-based biomarkers.

High Prevalence of CAA-Related Lesions in APOE ε4/4 Homozygotes With Early Alzheimer disease

Results suggest that the high burden of cerebral amyloid angiopathy-related lesions most likely underlies the 30%-60% incidence of amyloid-related imaging abnormalities in APOE e4/4 carriers treated with approved amyloid therapies.

Multiple Frameworks Better Interpret Alzheimer Trial Results to Meaningful Benefits

Based on a collection of data from clinical trials in Alzheimer disease, the best way to represent and translate the findings to meaningful benefits is through the use of multiple frameworks.

The Road to Precision Medicine in Alzheimer Disease Through Biomarkers: Hans J. Moebius, MD, PhD

The chief medical officer at Athira Pharma talked about an exploratory phase 2 trial that showcased the correlation between biomarkers for Alzheimer disease hallmarks and neuroinflammation. [WATCH TIME: 5 minutes]

NeuroVoices: Alessio Travaglia, PhD, on Utilizing Available Alzheimer Biomarkers Properly

The director at the Foundation for the National Institutes of Health provided perspective on the effective ways to utilize currently available biomarkers for Alzheimer disease research.

Efficacy of Antiamyloid Therapies Shown Over Long-Term Alzheimer Trajectory

A slowing of disease progression by 30% would result in clearly meaningful differences in patients with mild cognitive impairment and mild dementia.

Assessing the Impact of Gut Microbiota on Neuroprotection in Alzheimer Disease: Yannick J. Wadop Ngouongo, PhD

The postdoctoral researcher at The University of Texas Health Science Center at San Antonio talked the gut microbiome and neurological disorders, focusing on the potential role of gut microbiota imbalance in the pathogenesis of conditions like Alzheimer disease. [WATCH TIME: 5 minutes]

Insights on Gut Bacteria and Cognitive Health from Middle-Aged Adults: Jazmyn Muhammad, BS

The clinical research associate at the University of Texas Health Science Center at San Antonio discussed a study that explores the relationship between cognitive function and gut microbiome structure in middle-aged adults from the Framingham Heart Study cohort. [WATCH TIME: 4 minutes]

Advancing Research With Remote Blood Collection for Alzheimer Biomarkers: Hanna Huber, PhD

The researcher in the department of neurochemistry at the University of Gothenburg in Sweden discussed bloodspot cards as a promising method for collecting blood samples in Alzheimer disease research. [WATCH TIME: 4 minutes]

The Power of Diversity and Expanding the Genetic Landscape in Alzheimer Disease Research: Adam Naj, PhD

The genetic epidemiologist at the University of Pennsylvania talked about a collaboration of sites and analysis groups across the US to create a vast collection of genetic data on patients living with Alzheimer disease. [WATCH TIME: 5 minutes]

Diversifying Research and Improving Asian Representation With New Cohort Study for Alzheimer Disease

Li-San Wang, PhD, the Peter C. Nowell, MD, professor of pathology and laboratory medicine, Perelman School of Medicine at the University of Pennsylvania, discussed a study that aims to address the underrepresentation of Asian populations in Alzheimer disease research.

Diagnosing Alzheimer Disease With New Blood Tests in Primary Care Settings: Sebastian Palmqvist, MD, PhD

The associate professor of neuroscience at Lund University in Sweden discussed findings from a study of a new blood test examining biomarkers which demonstrated a high accuracy in identifying Alzheimer disease pathology. [WATCH TIME: 5 minutes]

Promising Therapeutic Developments for TDP-Related Pathologies: Sílvia Porta, PhD

The research assistant professor, pathology and laboratory medicine, University of Pennsylvania, talked about the ongoing research in her lab on understanding the mechanisms and consequences of TDP-43 aggregation in Alzheimer Disease. [WATCH TIME: 4 minutes]

Positive Progress Reported in ANeED Study of Ambroxol in Dementia With Lewy Bodies

Several patients have completed the 18-month trial and have moved on to the open-label extension, where they will be followed for an additional 12 months.

Revolutionizing Alzheimer Disease Diagnosis with Blood Biomarkers: Nicholas Ashton, PhD

The associate professor of neurochemistry at the University of Gothenburg in Sweden talked about a pilot study that explored the potential of finger prick tests to remotely collect blood and provide reliable biomarker results for Alzheimer disease diagnosis. [WATCH TIME: 5 minutes]

Overcoming Complexities With Cognitive Screening in Primary Care Centers: Nicole Fowler, PhD

The director of research for internal medicine and geriatrics at Indiana University School of Medicine provided perspective on ways to effectively streamline cognitive screening in timely and accurate manor. [WATCH TIME: 4 minutes]

Mortality Risk Significantly Increased With New Opioid Use in Older Adults With Dementia

In total, 33% of the study participants died within 180 days after initiating their first opioid prescription, compared with 6.4% of those unexposed.

Insights on Uncovering the Gut-Brain Interaction and Cognitive Function in Alzheimer Disease

Chaoran Ma, MD, PhD, assistant professor at University of Massachusetts Amherst, talked about the association between bowel movement frequency, the gut microbiome, and cognitive function in patients living with dementia.

Opioid Use and Mortality Risk in Older Patients with Dementia: Christina Jensen-Dahm, MD, PhD

The neurologist in the Danish Dementia Research Center at Rigshospitalet in Copenhagen, Denmark, discussed a cohort study that examined the association between opioid use and the risk of mortality in an older patient population living with dementia. [WATCH TIME: 5 minutes]

Potential Benefit of Nicotinamide Observed in Proof-Of-Concept Trial of Alzheimer Disease

Change in phosphorylated tau231, the primary outcome, favored nicotinamide despite not reaching statistical significance.

Alzheimer Disease Pipeline Update: Inside Look at Promising Agents

With the recent approval of lecanemab (Leqembi; Eisai), NeurologyLive took a closer look at the Alzheimer pipeline, and the potential agents clinicians should keep an eye on in the coming years.